6Perez EA, Romond EH, Suman VJ, et al. Four-year fallow-up of trastuzumab plus adjuvant chemotherapy for operable human epi- dermal growth factor receptor 2-positive breast cancer :joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011,29 (25) :3366-3373.
7Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer( NCCTG N9831, BCIRG 006,and BCIRG 005 ) [ J]. Breast Cancer Res Treat, 2013,138 ( 1 ) :99-108.
8Untch M, GeIber RD, 1ackisch C,et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial [ J ]. Ann Oncol,2008,19 (6) : 1090-1096.
9Purmonen Tr, Pankalainen E, Turunen JH, et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland:cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial [ J ]. Acta Oncol,2011,50(3) :344-352.
10Goldhirsch A, Gelber RD, Piccart-Gebhart M J, et al. 2 years versus 1 year of adjuvant trastuzumafi for HER2-positive breast cancer (HERA) : an open-label, randomised controlled trial [ J ]. Lancet, 2013,382(9897) :1021-1028.
